Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko in San Francisco, CA on April 7-8, 2015. Commissiong will be talking about the Lymphocyte Proliferation test (LymPro Test®), the Company’s proprietary Alzheimer's blood diagnosis technology, and about the firm's strategic plans for Amarantus Diagnostics. The session will take place from 10:30 to 11:30 a.m., Pacific Daylight Time. The discussion will be included in the Treatments for Alzheimer’s and Cognitive Disorders session, which will focus on neurodegenerative disorders and symptom improvement, disease modification and new options to diagnose such conditions accurately and earlier to improve outcomes. The LymPro test uses lymphocyte measurements as a sort of analogy of neuronal cell dysfunction. Combined with standard of care clinical measurements, the LymPro test can provide physicians with greater confidence that an Alzheimer’s diagnosis is accurate.